Nie Guangli, Chen Shiyun, Song Qingzhi, Zou Dongxu, Li Maggie, Tang Xiyu, Deng Yuanlian, Huang Bizhou, Yang Mengxia, Lv Guoqing, Zhang Yandong
Shenzhen KeYe Life Technologies Co., Ltd, Shenzhen, Guangdong 518000, China.
Shenzhen KeYe Life Technologies Co., Ltd, Shenzhen, Guangdong 518000, China; Southern University of Science and Technology, Shenzhen, China.
Biochim Biophys Acta Gen Subj. 2024 Mar;1868(3):130547. doi: 10.1016/j.bbagen.2023.130547. Epub 2023 Dec 22.
Tumor suppressor p53 is frequently null or mutated in human cancers. Here in this study, DHX33 protein was found to be induced in p53 null cells in vitro, and in p53 mutant lung tumorigenesis in vivo. Cholesterol metabolism through mevalonate pathway is pivotal for cell proliferation and is frequently altered in human cancers. Mice carrying mutant p53 and Kras alleles showed upregulation of mevalonate pathway gene expression. However upon DHX33 loss, their upregulation was significantly debilitated. Additionally, in many human cancer cells, DHX33 knockdown caused inhibition of mavelonate pathway gene transcription. We propose DHX33 locates downstream of mutant p53 and Ras to regulate mevalonate pathway gene transcription and thereby supports cancer development in vivo.
肿瘤抑制因子p53在人类癌症中经常缺失或发生突变。在本研究中,发现DHX33蛋白在体外p53缺失的细胞中以及在体内p53突变的肺癌发生过程中被诱导产生。通过甲羟戊酸途径的胆固醇代谢对细胞增殖至关重要,并且在人类癌症中经常发生改变。携带突变型p53和Kras等位基因的小鼠显示出甲羟戊酸途径基因表达上调。然而,在DHX33缺失后,它们的上调明显减弱。此外,在许多人类癌细胞中,DHX33基因敲低导致甲羟戊酸途径基因转录受到抑制。我们提出,DHX33位于突变型p53和Ras的下游,以调节甲羟戊酸途径基因转录,从而在体内支持癌症发展。